Last autumn, I was searching for a way to get rid of the nerve-zapping pain that hit every time the barometer made a steep jump. My face full of post-plane crash titanium and regenerated bone acted like a weather station….
Category Archives: Financing
What Global Financial Crisis? Capital Markets Back Biotechs
October 3, 2012 – 11:19 am
It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…
Where’s Rube Goldberg When You Need Him?
August 8, 2012 – 10:36 am
What’s the difference between Congress and a Rube Goldberg contraption?
Biotech Fundraising Slows in 1H12, Tougher Times Ahead?
July 9, 2012 – 11:35 am
There is no doubt that 2011 was a hot financing year for biotech and it was always going to be a tough act to follow.
A Stifled U.S. Biotech Sector: Is it Too Late to Recover?
June 20, 2012 – 4:37 pm
BOSTON ‑ Amid all of the excitement that comes with the biopharma industry’s largest annual gathering in Boston this week, I’m worried about the future. The U.S. has lost too much ground ‑ due to the obvious partisan gridlock in…
Biotech Fundraising Dips in Q112, But No Need to Panic
April 10, 2012 – 10:48 am
I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year.
Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?
March 15, 2012 – 10:46 am
The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire.
2010-12 Biotech IPOs Not Performing THAT Bad. Really.
March 12, 2012 – 3:50 pm
What a difference two weeks makes. When I was researching last week’s BioWorld Insight cover – about how emerging biotech Verastem Inc., mature biotech Ironwood Pharmaceuticals Inc. and specialty pharma firm Clovis Oncology Inc. shared some surprising similarities in how…
Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?
January 19, 2012 – 6:18 pm
When people talk about Johnson and Johnson’s new San Diego incubator, Janssen Labs, they can’t help but be a little bit skeptical about the fact that J&J isn’t taking any options or first-rights to compounds developed by its incubator tenants….
Five New Trends in Biotech Venture
January 17, 2012 – 6:46 pm
The cover story for BioWorld Insight this week is about the biotech venture capital world, and how despite its much-publicized contraction, there’s a lot of exciting stuff going on like established firms closing new funds, established players regrouping to form…
Join the Conversation